全文获取类型
收费全文 | 4348篇 |
免费 | 314篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 200篇 |
妇产科学 | 146篇 |
基础医学 | 494篇 |
口腔科学 | 94篇 |
临床医学 | 624篇 |
内科学 | 929篇 |
皮肤病学 | 72篇 |
神经病学 | 355篇 |
特种医学 | 341篇 |
外科学 | 384篇 |
综合类 | 183篇 |
一般理论 | 2篇 |
预防医学 | 297篇 |
眼科学 | 47篇 |
药学 | 297篇 |
中国医学 | 2篇 |
肿瘤学 | 200篇 |
出版年
2022年 | 30篇 |
2021年 | 72篇 |
2020年 | 45篇 |
2019年 | 73篇 |
2018年 | 86篇 |
2017年 | 57篇 |
2016年 | 61篇 |
2015年 | 71篇 |
2014年 | 101篇 |
2013年 | 149篇 |
2012年 | 189篇 |
2011年 | 171篇 |
2010年 | 146篇 |
2009年 | 137篇 |
2008年 | 146篇 |
2007年 | 164篇 |
2006年 | 169篇 |
2005年 | 172篇 |
2004年 | 163篇 |
2003年 | 182篇 |
2002年 | 160篇 |
2001年 | 157篇 |
2000年 | 139篇 |
1999年 | 144篇 |
1998年 | 98篇 |
1997年 | 80篇 |
1996年 | 78篇 |
1995年 | 61篇 |
1994年 | 61篇 |
1993年 | 60篇 |
1992年 | 96篇 |
1991年 | 81篇 |
1990年 | 77篇 |
1989年 | 90篇 |
1988年 | 92篇 |
1987年 | 80篇 |
1986年 | 82篇 |
1985年 | 90篇 |
1984年 | 33篇 |
1983年 | 33篇 |
1982年 | 29篇 |
1981年 | 27篇 |
1980年 | 31篇 |
1979年 | 46篇 |
1978年 | 38篇 |
1977年 | 32篇 |
1976年 | 38篇 |
1975年 | 25篇 |
1974年 | 25篇 |
1973年 | 35篇 |
排序方式: 共有4703条查询结果,搜索用时 15 毫秒
81.
The design and implementation of an assessment centre in the South Yorkshire and South Humberside deanery for selecting doctors into postgraduate training in paediatric medicine is described. Eleven competency domains were identified in the job analysis. An assessment centre comprising of four exercises was implemented to assess candidates. There were modest relationships between candidates' performance on the various assessment centre exercises. Outcomes based on interview performance were related to, but not the same as, outcomes based on the combined results of the three other assessment centre exercises. Candidates perceived the assessment centre to be a fair selection method. It is concluded that an assessment centre approach to SHO recruitment is feasible and provides a greater breadth and depth of information about candidates than does a structured interview. 相似文献
82.
Edvardas Kaminskas Ann Farrell Sophia Abraham Amy Baird Li-Shan Hsieh Shwu-Luan Lee John K Leighton Hasmukh Patel Atiqur Rahman Rajeshwara Sridhara Yong-Cheng Wang Richard Pazdur 《Clinical cancer research》2005,11(10):3604-3608
PURPOSE: This article summarizes data submitted to the U.S. Food and Drug Administration for marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation, Boulder, CO) for treatment of patients with myelodysplastic syndrome. EXPERIMENTAL DESIGN: In one phase 3 controlled trial, 191 study subjects were randomized to treatment with azacitidine or to observation; an additional 120 patients were treated with azacitidine in two phase 2 single arm studies. The primary efficacy end point was the overall response rate, defined as complete or partial normalization of peripheral blood counts and bone marrow blast percentages for at least 4 weeks. RESULTS: In the controlled trial, the overall response rate was 15.7% in the azacitidine treatment group; there were no responders in the observation group (P < 0.0001). Response rates were similar in the two single arm studies. During response patients stopped being red cell or platelet transfusion dependent. Median duration of responses was at least 9 months. An additional 19% of azacitidine-treated patients had less than partial responses, most becoming transfusion independent. The most common adverse events attributed to azacitidine were gastrointestinal, hematologic, local (injection site), and constitutional. There were no azacitidine-related deaths. CONCLUSIONS: On May 19, 2004 the U.S. Food and Drug Administration approved azacitidine as injectable suspension for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. Full prescribing information is available at http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf. Azacitidine is the first agent approved for treatment of myelodysplastic syndrome. 相似文献
83.
A L Hamilton J P Eder A C Pavlick J W Clark L Liebes R Garcia-Carbonero A Chachoua D P Ryan V Soma K Farrell N Kinchla J Boyden H Yee A Zeleniuch-Jacquotte J Wright P Elliott J Adams F M Muggia 《Journal of clinical oncology》2005,23(25):6107-6116
PURPOSE: We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to determine the recommended phase II dose and toxicity profile, and the extent of 20S proteasome inhibition obtained. PATIENTS AND METHODS: Patients with solid tumors or lymphomas were treated with bortezomib at 0.25 to 1.9 mg/m2 on D1 and D4, every 2 weeks. 20S proteasome levels in blood were assayed at baseline and at 1, 4, and 24 hours postdose in cycle 1. RESULTS: On this D1 and D4 every 2 weeks' schedule, dose-limiting toxicity (DLT) was evident at the 1.75 and 1.9 mg/m2 dose levels, most commonly in patients receiving individual total doses > or = 3.0 mg. The main DLT was peripheral neuropathy evident at the higher doses and in patients previously exposed to neurotoxic agents. Other DLTs included diarrhea and fatigue; grade 3 thrombocytopenia was also noted. Reversible inhibition of 20S proteasome activity was dose dependent and best fit a total dose (mg) per fraction rather than mg/m2; 70% of baseline activity was inhibited by a dose of 3.0 to 3.5 mg given on D1 and on D4 every other week. Antitumor effects short of confirmed partial responses were observed in patients with melanoma, non-small-cell lung cancer, and renal cell carcinoma. CONCLUSION: Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not exceeding 3.0 mg (equivalent to 1.75 mg/m2), repeated on D1 and D4 every other week. This dose correlates with 70% inhibition of 20S proteasome activity. DLTs include neuropathy, fatigue, and diarrhea. 相似文献
84.
Ariana Ghez Farrell Bernadeta Dadonaite Allison J. Greaney Rachel Eguia Andrea N. Loes Nicholas M. Franko Jennifer Logue Juan Manuel Carreo Anass Abbad Helen Y. Chu Kenneth A. Matreyek Jesse D. Bloom 《Viruses》2022,14(9)
Neutralization assays are experimental surrogates for the effectiveness of infection- or vaccine-elicited polyclonal antibodies and therapeutic monoclonal antibodies targeting SARS-CoV-2. However, the measured neutralization can depend on the details of the experimental assay. Here, we systematically assess how ACE2 expression in target cells affects neutralization by antibodies to different spike epitopes in lentivirus pseudovirus neutralization assays. For high ACE2-expressing target cells, receptor-binding domain (RBD) antibodies account for nearly all neutralizing activity in polyclonal human sera. However, for lower ACE2-expressing target cells, antibodies targeting regions outside the RBD make a larger (although still modest) contribution to serum neutralization. These serum-level results are mirrored for monoclonal antibodies: N-terminal domain (NTD) antibodies and RBD antibodies that do not compete for ACE2 binding incompletely neutralize on high ACE2-expressing target cells, but completely neutralize on cells with lower ACE2 expression. Our results show that the ACE2 expression level in the target cells is an important experimental variable, and that high ACE2 expression emphasizes the role of a subset of RBD-directed antibodies. 相似文献
85.
86.
87.
88.
单克隆抗体博来霉素A6偶联物对白血病细胞特异性结合与内化 总被引:2,自引:0,他引:2
抗CCT2单克隆抗体博来霉素A6偶联物可吸附胶体金颗粒(McAb-A6-Au)。电镜观察表明,在4℃,1h,表面有McAb-A6-Au颗粒的CEM细胞最高达78%;在37℃,4h,内化McAb-A6-Au颗粒的CEM细胞高达72%。而抗原性无关的U937细胞仅为14%。并且McAb-A6-Au颗粒能直接穿过细胞膜、核膜进入细胞浆和细胞核。37℃,1h已有10~18%的CEM细胞核内有McAb-A 6-Au颗粒。实验结果提示了单抗与博来霉素A6的偶联物与选择性地结合靶细胞,而且进入细胞速度快、穿透力强,有可能成为治疗白血病药物。 相似文献
89.
Secretion of matrix metalloproteinase‐3 by co‐cultured pigmented and non‐pigmented human trabecular meshwork cells following selective laser trabeculoplasty 下载免费PDF全文
90.
Growth and development of infants with end-stage renal disease receiving long-term peritoneal dialysis 总被引:1,自引:0,他引:1
B A Warady M Kriley H Lovell S E Farrell S Hellerstein 《The Journal of pediatrics》1988,112(5):714-719
The growth and development of four infants with end-stage renal disease receiving long-term peritoneal dialysis was studied during the first year of life. In each patient, dialysis was begun before 4 weeks of age. A nutritional regimen was designed to attain a daily weight gain appropriate for height age while minimizing the blood urea nitrogen level. A neurodevelopmental evaluation of gross and fine motor, cognitive, language, and psychosocial skills was performed at least every 3 months. At age 1 year, the mean height standard deviation score (SDS) was -1.33 +/- 0.2. Weight for height was greater than 95th percentile in one patient and normal in three. Mean caloric and protein intake were 105 +/- 20 kcal/kg/d (11.4 +/- 2.7 kcal/cm/d) and 2.7 g/kg/d (0.30 +/- 0.11 g/cm/d), respectively. Mean blood urea nitrogen was 53.6 +/- 17.8 mg/dL. Developmentally, three of the patients were functioning in the normal range and one was mildly retarded. However, gross motor skills were delayed in all patients. Although infants with end-stage renal disease are usually severely growth retarded and developmentally delayed, our observations suggest that early nutritional intervention and dialysis can yield improved results. 相似文献